Published in Drug Law Weekly, November 21st, 2006
GAAP net sales for the 2006 third quarter totaled $2.6 billion, up 13% versus the 2005 third quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck & Co., Inc., as the venture is accounted for under the equity method. Including an adjustment of an assumed 50% of global cholesterol joint venture net sales, Schering-Plough's adjusted net sales for the 2006 third...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.